Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: A preliminary report

Renal Failure

Volumn 37, Issue 1, 2015, Pages 175-179

  Schneider, Antoine G ^a,b   Schelleman, Anthony ^a   Goodwin, Mark D ^a   Bailey, Michael ^b   Eastwood, Glenn M ^a,c   Bellomo, Rinaldo ^a,b  

^a AUSTIN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Contrast enhanced ultrasonography; Hepato renal syndrome; Microcirculation; Renal perfusion; Terlipressin

Indexed keywords

BILIRUBIN; CREATININE; NORADRENALIN; SONOVUE; TERLIPRESSIN; ANTIHYPERTENSIVE AGENT; LYPRESSIN;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; ECHOGRAPHY; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY CIRCULATION; KIDNEY PERFUSION; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; IMAGE ENHANCEMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CORTEX; MICROCIRCULATION; PROCEDURES; SCINTIGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, INTRAVENOUS; ANTIHYPERTENSIVE AGENTS; HEPATORENAL SYNDROME; HUMANS; IMAGE ENHANCEMENT; KIDNEY CORTEX; LYPRESSIN; MALE; MICROCIRCULATION; MIDDLE AGED; PERFUSION IMAGING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84919461653     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.977140     Document Type: Article

References (15)

1. Martin-Llahi M, Pepin M-N, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology. 2008; 134(5):1352-1359.
2. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008; 134(5):1360-1368.
3. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-1290.
4. Schrier RW, Niederberger M, Weigert A, Gines P. Peripheral arterial vasodilatation: Determinant of functional spectrum of cirrhosis. Semin Liver Dis. 1994;14(1):14-22.
5. Fabrizi F, Dixit V, Martin P. Meta-analysis: Terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006; 24(6):935-944.
6. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9: CD005162.
7. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97(5):473-483.
8. Tiemann K, Becher H, Lohmeier S. Real-time assessment of tissue perfusion following bubble destruction at low emission-power-First experimental results using power pulse inversion imaging. J Am Coll Cardiol. 2000;35:426A.
9. Schneider AG, Hofmann L, Wuerzner G, et al. Renal perfusion evaluation with contrast-enhanced ultrasonography. Nephrol Dial Transplant. 2012;27(2):674-681.
10. Kishimoto N, Mori Y, Nishiue T, et al. Renal blood flow measurement with contrast-enhanced harmonic ultrasonography: Evaluation of dopamine-induced changes in renal cortical perfusion in humans. Clin Nephrol. 2003;59(6):423-428.
11. Schneider AG, Goodwin MD, Schelleman A, Bailey M, Johnson L, Bellomo R. Contrast-enhanced ultrasound to evaluate changes in renal cortical perfusion around cardiac surgery: A pilot study. Crit Care. 2013;17(4):R138.
12. Schneider A, Johnson L, Goodwin M, Schelleman A, Bellomo R. Bench-to-bedside review: Contrast enhanced ultrasonography-A promising technique to assess renal perfusion in the ICU. Crit Care. 2011;15(3):157.
13. Arditi M, Frinking PJ, Zhou X, Rognin NG. A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control. 2006;53(6):1118-1129.
14. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-226.
15. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315-321.